Device Trial Radar · NCT05757102
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
138
Planned (sponsor's estimate)
Start
Apr 24, 2023
Primary completion
Jan 26, 2027
Study completion Jan 28, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Conditions
- Asthma
Interventions
FF/UMEC/VIDrug
FF/UMEC/VI will be administered.
ELLIPTADevice
FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler
FF/VIDrug
FF/VI will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in trough forced expiratory volume in 1 second (FEV1) (Liters) at Week 24Time frame: Baseline (Week 0) and Week 24
Locations
67 sites in 9 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Paradise Valley, Arizona
64 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.